Silverback Therapeutics Inc. (SBTX) News
Filter SBTX News Items
SBTX News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Latest SBTX News From Around the Web
Below are the latest news stories about SILVERBACK THERAPEUTICS INC that investors may wish to consider to help them evaluate SBTX as an investment opportunity.
Once A Cancer Company, Silverback Merges With Small Biotech Working On Allergy TreatmentARS Pharmaceuticals Inc will merge with Silverback Therapeutics Inc (NASDAQ: SBTX) in an all-stock transaction, with a new entity operating under the ARS Pharmaceuticals name and trade on NASDAQ under the SPRY symbol. The combined company will focus on neffy, ARS's investigational epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. The combined entity is expected to have approximately $265 million in cash and equivalents at closing. Also Read: Silverback Therapeutics Ax |
Silverback Therapeutics and ARS Pharmaceuticals Announce MergerSEATTLE & SAN DIEGO, July 21, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS") today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis. T |
What You Need To Know About Silverback Therapeutics, Inc.'s (NASDAQ:SBTX) Investor CompositionThe big shareholder groups in Silverback Therapeutics, Inc. ( NASDAQ:SBTX ) have power over the company. Large... |
Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceSEATTLE, May 17, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright 24th Global Investment Conference from May 23-25, 2022. |
JonesTrading Keeps Their Hold Rating on Silverback Therapeutics (SBTX)JonesTrading analyst Soumit Roy maintained a Hold rating on Silverback Therapeutics (SBTX – Research Report) on May 13. The company's shares closed last Friday at $2.96, close to its 52-week low of $2.80. According to TipRanks.com, Roy is a 3-star analyst with an average return of 3.2% and a 28.5% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Silverback Therapeutics with a $3.43 average price target, an 11.0% upside from current levels. In a report issued on May 13, H.C. |
H.C. Wainwright Keeps a Hold Rating on Silverback Therapeutics (SBTX)E ratio of…. |
Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateSEATTLE, May 12, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a business update. |
Is Silverback Therapeutics (NASDAQ:SBTX) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial ResultsSEATTLE, March 31, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today provided an update on strategic priorities and reported financial results for the fourth quarter and full year ended December 31, 2021. |
Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare ConferenceSEATTLE, February 24, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that members of the Silverback management team will participate in the 42nd Annual Cowen Healthcare Conference from March 7-9, 2022. |